Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC).
Ayca Gucalp(Institute of Cancer Research), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Andres Forero‐Torres(Kirklin Clinic), Minetta C. Liu(Mayo Clinic), Lamia F. Momen(Memorial Sloan Kettering Cancer Center), Clifford A. Hudis(American Society of Clinical Oncology), Lisa A. Carey(University of North Carolina at Chapel Hill), Kimberly Feigin(Memorial Sloan Kettering Cancer Center), Vered Stearns(Johns Hopkins University), Sara M. Tolaney(Harvard University), James N. Ingle(Mayo Clinic), Hope S. Rugo(City of Hope), Sujata Patil(Dr. D. Y. Patil Medical College, Hospital and Research Centre), Dilip D. Giri(Memorial Sloan Kettering Cancer Center), Joseph Gonzalez(Memorial Sloan Kettering Cancer Center), Kimberly Blackwell(Duke University), Steven J. Isakoff(Harvard University)
Cited by 31
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k